

CURE ID

January Newsletter

Investigate drug repurposing opportunities to treat challenging infections! Share your successes and challenges with difficult to treat infections.


Happy New Year!



Spotlight: Three of our New Social Media Ambassadors



Tamara Tango is an International Medical Graduate from Faculty of Medicine Universitas Indonesia. She aspires to pursue a career as a clinician-researcher. She graduated with a Master of Research (M.Res) focused in Neuroscience from Newcastle University, UK. Through becoming CURE ID's Social Media Ambassador, she looks forward to delivering the updated news about infectious diseases and collaborating with other researchers. Email: tamara.tango@alumni.ui.ac.id



Dimitrios Kantas graduated from Medical School of Ioannina, Greece in 2010. Then, pursued a fellowship in pulmonary and critical care medicine at University Hospital of Ioannina and one year fellowship in pulmonary and sleep medicine at University Hospitals Birmingham, UK. Also, he received a MSc in sleep medicine from National and Kapodistrian University of Athens, Greece. Currently, Dimitris is a European board certified pulmonologist/intensivist-somnologist, research fellow/collaborator at Mayo Clinic in Rochester, Minnesota, and since 2019 PhD candidate working on an R01 grant on sleep cardiovascular risk and racial differences. He is secretary of group 4.01(Sleep science- basic and translational) of European Respiratory Society (ERS) sleep assembly 4, member of the Political Action Committee (PAC) advisory panel, young investigators forum and board review committee of the American Academy of Sleep Medicine (AASM) and serves as international ambassador of AASM for Europe. Furthermore, he serves as member of the Diversity, Equity and Inclusion Committee of Sleep Research Society (SRS) and Chair of Diversity and Inclusion Committee of the American College of Health Executives (ACHE) in Minnesota area. He is an associate editor of the REM section of the Journal of Clinical Sleep Medicine (JCSM), member of the editorial board of Nature and Science of Sleep and serves as a reviewer for most of major sleep medicine journals. Young and enthusiastic physician/researcher musician and dreamer!



Ifra Saifi is a Research Intelligence Analyst and certified botanist with a passion for data analysis and drug discovery. She has completed an internship at Uresearcher Growth Labs, where she gained expertise in data collection, dataset curation, web scraping, and data cleaning. She has also participated in the D-Challenge, an international competition in which teams generate novel hypotheses using rich, curated data sets. In addition to her work experience, Ifra has received several scholarships to further her education in areas such as cloud computing and data science. She is constantly seeking to learn and expand her knowledge and skill set.

CURE ID/CDRC Social Media Ambassador

Looking to become a social media ambassador?

CURE ID is looking to recruit individuals interested in help promoting our web-based app. The platform enables healthcare providers to share their real-world experiences treating patients with repurposed drugs. We currently have 20 social media ambassadors and looking to expand.

This is an unpaid position but can win CURE ID/CDRC swag.

This is a competitive opportunity to bring on more followers, tweets, discussion posts, and win some swag!

If interested please reach out to cbassetti@cpath.org


CURE ID Projects for 2023



Great things are coming in 2023 including:

- EHR Data Extraction
- Oncology
- Rare Disease
- Patient Case Report Form
- Treatment of Long Covid Survey
- Stay tuned!

Save the date



CURE Drug Repurposing Collaboratory Annual Meeting

April 18th- 20th, 2023. Hyatt Regency Crystal City

2799 Richmond Highway - Arlington, Virginia 22202

Registration and details coming soon!



Upcoming/Recent Events

CURE ID celebrated its 3rd anniversary on December 5th



In the past:

The Future of Health Summit

Partnering for Patients, a Forum of the Future of Health Summit

December 6th-8th 2022. Washington, DC.

"Creating New Markets for Approved Drugs"

roundtable discussion, Heather Stone

Summary: the Future of Health Summit will feature the insights of hundreds of speakers, including top leaders in public health, biomedical research, philanthropy, science, and policy to discuss how we both build upon the profound progress and tackle the remaining challenges illuminated by the pandemic.

15th Annual Conference on the Science of Dissemination and Implementation in Health.

December 11-14 2022. Academy Health, Washington, DC

<https://drugrepositioningconference.com/index/>

Coming up:

2023 Critical Care Congress

January 21-24, 2023. The Moscone Center South in San Francisco, CA

Smitty Heavner: Leveraging the SCCM Discovery VIRUS COVID-19 Registry to

Evaluate Drug Repurposing Research Dataset.

<https://www.sccm.org/Congress>

Publication from CDRC team members

[Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports](#) (Author, Reema Charles & Marco Schito are on the CDRC team)

Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports

Reema Charles¹, Shreya Das Kulkarni², Ankur Mittal³, Souvik Chaudhuri⁴, Mukund Gupta⁵, Wasim Kheir⁶, Marco Schito⁷, Nitesh Gupta⁸
¹CDRC Drug Repurposing Collaborative (CDRC), Critical Path Institute, Fairfax, VA, USA;
²Department of Pharmacy, Kanchi Medical College and Hospital, Chennai, India;
³Department of Medicine, All India Institute of Medical Sciences, New Delhi, India;
⁴Department of Clinical Pharmacy, Kanchi Medical College and Hospital, Chennai, India;
⁵Department of Clinical Pharmacy, Kanchi Medical College and Hospital, Chennai, India;
⁶Department of Clinical Pharmacy, Kanchi Medical College and Hospital, Chennai, India;
⁷Department of Clinical Pharmacy, Kanchi Medical College and Hospital, Chennai, India;
⁸Department of Clinical Pharmacy, Kanchi Medical College and Hospital, Chennai, India
Article received 27 May 2022; accepted 21 October 2022

SUMMARY

Introduction: The emergence of antibiotic resistance has forced clinicians to consider the use of drugs not approved to treat urinary tract infections (UTIs). Tigecycline is a novel tetracycline antibiotic that has been approved for use in the United States and Europe. A systematic review of published case reports was conducted to evaluate the efficacy of tigecycline in the treatment of UTIs. **Methods:** A systematic review of published case reports was conducted to evaluate the efficacy of tigecycline in the treatment of UTIs. **Results:** Of the 75 cases, 66 were female and 9 were male. The most common organism was *Klebsiella pneumoniae* (n = 35), followed by *Escherichia coli* (n = 15) and *Acinetobacter baumannii* (n = 11). Tigecycline was used as monotherapy in 10 patients and as a combination therapy in 65 patients. The median duration of tigecycline was 13 (10–17) days. The median duration of clinical response was 10 (7–14) days. The median duration of clinical response was 10 (7–14) days. The median duration of clinical response was 10 (7–14) days. **Conclusion:** Tigecycline was used as monotherapy in 10 patients and as a combination therapy in 65 patients. The median duration of tigecycline was 13 (10–17) days. The median duration of clinical response was 10 (7–14) days. The median duration of clinical response was 10 (7–14) days. **Keywords:** UTI, tigecycline, antibiotic resistance, CDRC, ACME.

Trending Articles


Descriptive Data On Trends Among Patients Hospitalized With Lyme Disease In Southwest Michigan, 2017-2021

[Open Forum Infectious Diseases | Oxford Academic \(oup.com\)](#)

WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment

[2022 update](#)

Awareness Month



Be Heard: Tell Your Drug Repurposing Story in 2023!

Our Impact stories share the value and impact C-Path's and CDRC's work brings to patients, patient organizations, drug developers, the academic community, regulators and more. Enjoy and share! [Impact Stories | Critical Path Institute \(c-path.org\)](#)

Reach out to the Communication and Patient Engagement Manager, Claire Bassetti at cbassetti@cpath.org if interested in sharing your story through an Impact Story.

Joining the CDRC



The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

If interested, please feel free to get involved with the CURE Drug Repurposing Collaboratory (CDRC),
here: <https://c-path.org/cdrc>

CDRC Industry Collaborators



CDRC Academic Collaborators



CDRC All other Collaborators






Visit CURE ID App

Visit the CURE ID website for more information. <https://cure.ncats.io>



Brought to you by



You are receiving this email as a member of CURE ID. If you have any questions regarding this communication, please contact us at curesupport@nih.gov



Copyrights © 2023 CURE ID. All Rights Reserved